In particular, studies showed that combining CDK9 inhibition with ICB increases both T cell and antigen-presenting cell (APC) activation and function compared to ICB alone, demonstrating a function of CDK9 in modulating tumor microenvironment 19. Here, CDK9 is linked to neoplasm.